Cardiovascular molecular imaging: New methodological strategies

Current Pharmaceutical Design

Volumn 19, Issue 13, 2013, Pages 2439-2446

  Santarelli, Maria Filomena ^a,b   Positano, Vincenzo ^b   Menichetti, Luca ^a,b   Landini, Linda ^c   Landini, Luigi ^b,c  

^a INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^b FONDAZIONE TOSCANA GABRIELE MONASTERIO   (Italy)

^c UNIVERSITY OF PISA   (Italy)

Author keywords

Cardiovascular molecular imaging; Dual modality probes; Hybrid scanners; Hyperpolarized 13C; Imaging techniques; Multimodal imaging

Indexed keywords

COPPER 64; FLUORINE 18; GALLIUM 68; IODINE 124;

CARBON NUCLEAR MAGNETIC RESONANCE; CARDIAC IMAGING; CARDIOVASCULAR MAGNETIC RESONANCE; ECHOGRAPHY; FLUORESCENCE IMAGING; HUMAN; MOLECULAR IMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

CARDIOVASCULAR SYSTEM; HUMANS; MOLECULAR IMAGING;

EID: 84877837842     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319130012     Document Type: Review

References (94)

1. Jaffer FA, Libby P, Weissleder R. Molecular Imaging of Cardiovascular Disease. Circulation 2007; 116: 1052-61
2. Landini L, Santarelli MF, Positano V, et al. Molecular Imaging: It's Application In Cardiovascular Diagnosis. Curr Pharm Des 2005; 11(17): 2225-34
3. Landini L, Santarelli MF, Pingitore A, et al. New technological developments in the clinical imaging of atherosclerotic plaque. Curr Pharm Des 2003; 9 (29): 2403-15
4. de Kemp RA, Epstein FH Catana C, Tsui BMW, and Ritman EL. Small-Animal Molecular Imaging Methods. J Nucl Med 2010; 51: 18S-32S.
5. Buxton DB, Antman M, Danthi N, et al. Report of the National Heart, Lung, and Blood Institute Working Group on the Translation of Cardiovascular Molecular Imaging. Circulation 201123(19): 2157-63
6. Ghosh N, Rimoldi OE, Beanlands RSB, et al. Assessment of myocardial ischaemia and viability: role of positron emission tomography. Eur Heart J 2010, doi: 10.1093/eurheartj/ehq361.
7. Tamaki N, Yoshinaga K. Novel iodinated tracers, MIBG and BMIPP, for nuclear cardiology. Journal of Nuclear Cardiology 2011; 18(1): 135-43
8. Sinusas AJ, Thomas JD, Mills G. The Future of Molecular Imaging. J. Am. Coll. Cardiol. Img 2011,4: 799-806
9. Chen IY and Wu JC. Cardiovascular Molecular Imaging: Focus on Clinical Translation. Circulation 2011; 123: 425-43
10. Marinelli M, Positano V, Tucci F, et al. Automatic PET-CT image registration method based on mutual information and genetic algorithms. The ScientificWorld Journal 2012, doi: 10.1100/2012/567067.
11. Sinusas AJ. Multimodality Cardiovascular Molecular Imaging: An Overview. J Nucl Med 2010; 51: 1S-2S
12. Zaidi H, Prasad R. Advances in multimodality molecular imaging. J Med Phys 2009; 34(3): 122-8.
13. Lee WW, Marinelli B, van der Laan AM, et al. PET/MRI of Inflammation in Myocardial Infarction. J Am Coll Cardiol 2012; 59(2): 153-63.
14. Marinelli M, Positano V, SG Nekolla, et al. Hybrid Image Visualization Tool for 3D integration of CT coronary anatomy and quantitative myocardial perfusion PET. International Journal of Computer Assisted Radiology and Surgery (JCARS) 2012. DOI: 10.1007/s11548-012-0777-3
15. Marinelli M, Martinez-Moller A, Jensen B, et al. Registration of Myocardial PET and SPECT for Viability Assessment using Mutual Information. Medical Physics 2010; 37: 2414-24
16. Wagner B, Anton M, Nekolla SG, et al. Noninvasive Characterization of Myocardial Molecular Interventions by Integrated Positron Emission Tomography and Computed Tomography. J of Am Coll Cardiol, 2006; 48(10): 2107-15.
17. Nekolla SG, Martinez-Moeller A, Saraste A. PET and MRI in cardiac imaging: from validation studies to integrated applications. Eur J Nucl Med Mol Imaging 2009; 36(Suppl 1): S121-30.
18. Dobrucki LW and Sinusas AJ. PET and SPECT in cardiovascular molecular imaging. J. Nat. Rev. Cardiol 2010; 7: 38-47.
19. Sinusas AJ, Bengel F, Nahrendorf M, et al. Multimodality cardiovascular molecular imaging, part I. Circ Cardiovasc Imaging 2008; 1(3): 244-56.
20. Nahrendorf M, Sosnovik DE, French BA, et al. Multimodality Cardiovascular Molecular Imaging, Part II. Circ Cardiovasc Imaging 2009; 2: 56-70.
21. Sosnovik DE, Nahrendorf M, Deliolanis N, et al. Fluorescence tomography and magnetic resonance imaging of myocardial macrophage infiltration in infarcted myocardium in vivo. Circulation 2007; 115: 1384-91.
22. Sosnovik DE. Molecular Imaging of Myocardial Injury: A Magnetofluorescent Approach. Curr Cardiovasc Imaging Rep 2009, 2(1): 33-9.
23. Wen-Yen H, and Davis JJ. Multimodality and nanoparticles in medical imaging. Dalton Trans 2011; 40: 6087-103.
24. Menichetti L, Frijia F, Flori A, et al. Assessment of real-time myocardial uptake and enzymatic conversion of hyperpolarized [1-13C]pyruvate in pigs with slice selective Magnetic Resonance Spectroscopy. Contrast Media and Molecular Imaging, 2012, 7(1): 85-94.
25. Schroeder M.A., Atherton H.J., Ball D.R., et al. Real-time assessment of Krebs cycle metabolism using hyperpolarized 13C magnetic resonance spectroscopy. FASEB J, 2009; 23(8): 2529-3258.
26. Frijia F, Wiesinger F, Santarelli MF, et al. Detection of 3D Cardiac metabolism after injection of hyperpolarized [1-13C]pyruvate. Journal of Cardiovascular Magnetic Resonance 2011,13(Suppl 1): M2.
27. Inubushi M., Tamaki N. Radionuclide reporter gene imaging for cardiac gene therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2007; 34: S27-33.
28. Agostini S, Recchia F, Lionetti F. Molecular Advances in Reporter Genes: The Need to Witness the function of Stem Cells in Failing Heart in vivo. Stem Cell Rev and Rep 2012; 8: 503-512.
29. Rahmim A, and Zaidi H. PET versus SPECT: strengths, limitations and challenges. Nucl Med Commun 2008; 29(3): 193-207.
30. Winter PM, Caruthers SD, Lanza GM, et al. Quantitative cardiovascular magnetic resonance for molecular imaging. Journal of Cardiovascular Magnetic Resonance 2010; 12: 62 doi: 10.1186/1532-429X-12-62
31. Positano V, Pepe A, Santarelli MF, et al. Multislice multiecho T2* cardiac magnetic resonance for detection of heterogeneous myocardial iron distribution in thalassemia patients. NMR in Biomedicine 2009; 22: 707-15.
32. Aquaro GD, Masci P, Formisano F, et al. Usefulness of Delayed Enhancement by Magnetic Resonance Imaging in Hypertrophic Cardiomyopathy as a Marker of Disease and Its Severity. American Journal of Cardiology 2010; 105: 392-7.
33. Engberink RDO, van der Pol SMA, de Vries HE, et al. Comparison of SPIO and USPIO for in vitro Labeling of Human Monocytes: MR Detection and Cell Function. Radiology 2007; 243: 467-74.
34. Tsuchiya K, Nitta N, Sonoda A, et al. Histological study of the biodynamics of iron oxide nanoparticles with different diameters. International Journal of nanomedicine 2011; 6: 1587-94.
35. Kotek G, van Tiel ST, Wielopolski PA, et al. Cell quantification: evolution of compartmentalization and distribution of iron-oxide particles and labeled cells. Contrast Media & Molecular Imaging, 2012; 7(2): DOI: 10.1002/cmmi.481
36. Calducci L, Cofani G, De Marchi D, et al. Boron Nitride Nanotubes as T2-Weighted MRI Contrast different diameters. International Journal of nanomedicine 2011; 6: 1587-94.
37. Moestue SA, Gribbestad IS and Hansen R. Intravascular Targets for Molecular Contrast-Enhanced Ultrasound Imaging. Int. J. Mol. Sci 2012; 13: 6679-97.
38. Lindner JR. Molecular Imaging of Myocardial and Vascular Disorders With Ultrasound. Cardiovascular Imaging 2010; 3(2): 204-11.
39. Lin S, Xie X, Patel MR, et al. Quantum dot imaging for embryonic stem cells. BMC Biotechnol 2007; 7: 67. doi: 10.1186/1472-6750-7-67
40. Gao X, Yang L, Petros JA, et al. In vivo molecular and cellular imaging with quantum dots. Curr Opin Biotech 2005; 16: 63-72.
41. Calfon MA, Vinegoni C, Ntziachristos V, et al. Intravascular nearinfrared fluorescence molecular imaging of atherosclerosis: toward coronary arterial visualization of biologically high-risk plaques. Journal of Biomedical Optics 2010; 15(1): 011107. doi: 10.1117/1.3280282.
42. Close DM, Xu T, Sayler et al. In vivo Bioluminescent Imaging (BLI): Noninvasive visualization and Interrogation of Biological Processes in Living Animals. Sensors 2011; 11: 180-206.
43. Hyafil F, Cornily JC, Feig JE, et al. Noninvasive detection of macrophages using a nanoparticulate contrast agent for computed tomography. Nature Medicine, 2007; 13: 636-641.
44. Cormode DP, Skajaa T, van Schooneveld MM, et al. Nanocrystal core high-density lipoproteins: A multimodality contrast agent platform. Nano Lett 2008; 8(11): 3715-23.
45. Franc BL, Acton PD, Mari C, et al. Small-Animal SPECT and SPECT/CT: Important Tools for Preclinical Investigation. J Nucl Med 2008; 49: 1651-63
46. Del Guerra A, Belcari N. State-of-the-art of PET, SPECT and CT for small animal imaging. Nuclear Instruments and Methods in Physics Research A 2007; 583: 119-24.
47. Tsui BMW, and Kraitchman DL. Recent Advances in Small-Animal Cardiovascular Imaging. J Nucl Med 2009; 50: 667-70.
48. van Werkhoven JM, Schuijf JD, Gaemperli O, et al. Prognostic value of multi-slice computed tomography and gated single photon emission computed tomography in patients with suspected coronary artery disease. J Am Coll Cardiol 2009; 53: 623-32.
49. Gaemperli O, Bengel FM, and Kaufmann PA. Cardiac hybrid imaging. Eur. Heart J 2011; 32: 2100-8.
50. Kaufmann PA. Cardiac hybrid imaging: state-of-the-art. Ann Nucl Med 2009; 23: 325-31.
51. Nekolla S, Martinez-Moeller A, Saraste A. PET and MRI in cardiac imaging: from validation studies to integrated applications. Eur J Nucl Med 2009; 36(Suppl 1): S121-S130
52. Shao Y, Cherry S. R, Farahani K, et al. Simultaneous PET and MR imaging. Phys. Med. Biol 1997; 42: 1965-70.
53. Beyer T, Freudenberg LS, Czernin J, et al. The future of hybrid imaging-part 3: PET/MR, small-animal imaging and beyond. Insights Imaging 2011; 2: 235-46.
54. Hofmann M, Pichler B, Schölkopf B, et al. Towards quantitative PET/MRI: a review of MR-based attenuation correction techniques. Eur J Nucl Med Mol Imaging 2009; 36(Suppl 1): S93-S103
55. Herzog H, Pietrzyk U, Shah NJ, et al. The current state, challenges and perspectives of MR-PET. NeuroImage 2010; 49: 2072-82
56. Lee DE, Koo H, Sun IC, et al. Multifunctional nanoparticles for multimodal imaging and theragnosis,. Soc Rev 2012; 41: 2656-72.
57. Liu Y and Welch MJ. Nanoparticles Labeled with Positron Emitting Nuclides: Advantages, Methods, and Applications, Bioconjugate Chem 2012; 23: 671-82.
58. 64Culabeled polymer nanoparticles targeted to the lung endothelium. J Nucl Med 2008; 49: 103-11
59. 64cuII-bis (dithiocarbamatebisphosphonate) and its conjugation with superparamagnetic iron oxide nanoparticles: In vivo evaluation as dualmodality PET-MRI agent, Angew Chem Int Ed 2011; 50: 5509-13
60. Tassa C, Shaw SY, and Weissleder R. Dextran-coated iron oxide nanoparticles: a versatile platform for targeted molecular imaging, molecular diagnostics, and therapy. Acc Chem Res 2011; 44(10): 842-52.
61. Yankeelova TE, Petersona TE, Abramsona RJ, et al. Simultaneous PET-MRI in oncology: a solution looking for a problem?. Magneti Res Med 2012; 30(9): 1342-56.
62. 64Cu-Labeled Magnetic Nanoparticles as a Dual-Modality PET/MR Imaging Agent. Bioconjugate Chem 2010; 21(4): 715-22.
63. Choi JS, Park JC, Nah H, et al. A Hybrid Nanoparticle Probe for Dual-Modality Positron Emission Tomography and Magnetic Resonance Imaging. Angew Chem Int Ed 2008; 47: 6259-62.
64. Lee HY, Li Z, Chen K, et al. PET/MRI dual-modality tumor imaging using arginine-glycine-aspartic (RGD)-conjugated radiolabeled iron oxide nanoparticles. J Nucl Med 2008; 49(8): 1371-9
65. Jarrett BR, Gustafsson B, Kukis DL, et al. Synthesis of 64Culabeled magnetic nanoparticles for multimodal imaging. Bioconjug Chem 2008; 19(7): 1496-504
66. Xie J, Huang J, Li X, et al. Iron oxide nanoparticle platform for biomedical applications. Curr Med Chem 2009; 16: 1278-94
67. 64Cu-labeled superparamagnetic iron oxide nanoparticles for targeted anticancer drug delivery and PET/MR imaging. Biomaterials, 2011; 32(17): 4151-60.
68. Liu Y and Welch MJ. Bioconjugate Chemistry 2012; 23: 671-82.
69. Frullano L, Catana C, Benner T, et al. Bimodal MR-PET agent for quantitative pH imaging. Angew Chem Int Ed Engl 2010; 49(13): 2382-4.
70. Uppal R, Ciesienski KL, Chonde DB, et al. Discrete Bimodal Probes for Thrombus Imaging, Journal of the American Chemical Society 2012; 134(26): 10799-802.
71. Uppal R, Catana C, Ay I, Benner T, et al. Bimodal thrombus imaging: simultaneous PET/MR imaging with a fibrin-targeted dual PET/MR probe. Feasibility study in rat model. Radiology 2011; 258: 812-20.
72. Gianella A, Read JC, Cormode DP, et al. Multifunctional Nanoparticles for Drug Delivery Applications. Nanostructure Science and Technology 2012; Part 3, 155-171, DOI: 10.1007/978-1-4614-2305-8_8.
73. de Vries A, Kok MB, Sanders HMHF, et al. Multimodal liposomes for SPECT/MR imaging as a tool for in situ relaxivity measurements. Contrast Media Mol. Imaging 2011; 7(1): 68-75.
74. Bhattacharya P, Ross BD, Bünger R. Cardiovascular applications of hyperpolarized contrast media and metabolic tracers. Experimental Biology and Medicine 2009; 234: 1395-416.
75. Bowers CR, Weitekamp DP. Para-hydrogen and synthesis allow dramatically enhanced nuclear alignment. J Am Chem Soc 1987; 109: 5541-2.
76. Abragam A, Goldman M. Principles of dynamic nuclearpolarization. Rep Prog Phys 1978; 41: 395-467.
77. Flori A, Frijia F, Lionett V, et al. DNP Methods for Cardiac Metabolic Imaging with Hyperpolarized [1-13C]pyruvate Large Dose Injection in Pigs. Applied Magnetic Resonance 201; 43: 299-310.
78. Day S, Kettunen MI, Gallagher FA, et al. Detecting tumor response to treatment using hyperpolarized 13C magnetic resonance imaging and spectroscopy. Nat Med, 2007; 13: 1382-7.
79. Tyler D.J. Cardiovascular Applications of Hyperpolarized MRI. Curr Cardiovasc Imaging Rep 2011; 4: 108-15.
80. Schroeder MA, Clarke K, Neubauer S, et al. Hyperpolarized magnetic resonance. A novel technique for the in vivo assessment of cardiovascular disease. Circulation 2011; 124: 1580-94.
81. Aquaro G D, Frijia F, Positano V, et al. Three-dimensional magnetic resonance mapping of cardiac metabolism by hyperpolarized 13C-pyruvate in a pig model of ischemiareperfusion. JAAC: Cardiovascular Imaging, in press 2013.
82. Merritt ME, Harrison C, Storey C, et al. Hyperpolarized 13C allows a direct measure of flux through a single enzyme-catalyzed step by NMR. Proc Natl Acad Sci USA 2007; 104: 19773-7.
83. Schroeder MA, Cochlin LE, Heather LC, et al. In vivo assessment of pyruvate dehydrogenase flux in the heart using hyperpolarized carbon-13 magnetic resonance. Proc Natl Acad Sci USA 2008; 105(33): 12051-6.
84. Tyler DJ, Schroeder MA, Cochlin LE, et al. Application of hyperpolarized magnetic resonance in the study of cardiac metabolism. Applied Magnetic Resonance, 2008; 34(3-4): 523-31.
85. 3. Magn Reson Med 2008; 60(5): 1029-36.
86. 13C MRI. Magn Reson Med 2008; 59: 1005-13.
87. 13C pyruvate and bicarbonate in the heart. Magn Reson Med 2010; 64(5): 1323-31.
88. Cunningham CH, Chen AP, Lustig M, et al. Pulse sequence for dynamic volumetric imaging of hyperpolarized metabolic products. J Magn Reson 2008; 193: 139-46.
89. Wiesinger F, Weidl E, Menzel MI, et al. IDEAL spiral CSI for dynamic metabolic MR imaging of hyperpolarized [1-(13) C]pyruvate. Magn Reson Med 2012; 68(1): 8-16.
90. 13C Studies. Magn Reson Med 2011; 65(3): 610-9.
91. 13C dynamic MRS data fitting and parameter estimation. NMR Biomed 2012; 25: 925-34.
92. 13C MRS surface coil: design and signal-to-noise ratio estimation. Med Phys 2010; 37(10): 5361-9.
93. 13C MRS cardiac metabolism studies in pigs: comparison between surface and volume radiofrequency coils. Applied Magnetic Resonance 2012; 42(3): 413-28.
94. 13C MRI assist clinical decision-making for patients with heart disease? NMR Biomed 2011; 24(8): 973-9.